We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to ...

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Highlights,Sarepta Therapeutics continues to expand its RNA-targeted and gene therapy treatments for rare ...

In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market ...

Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across seven major markets, driven by recent approvals of novel therapies, says ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's ...

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...